Compare SSTK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | MNPR |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.9M | 587.4M |
| IPO Year | 2012 | 2019 |
| Metric | SSTK | MNPR |
|---|---|---|
| Price | $9.85 | $96.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $25.00 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 643.0K | 144.8K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | 23.76 | ★ 54.99 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.43 | $29.18 |
| 52 Week High | $29.50 | $105.00 |
| Indicator | SSTK | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 27.75 | 82.98 |
| Support Level | N/A | $52.92 |
| Resistance Level | $17.60 | $103.17 |
| Average True Range (ATR) | 0.82 | 6.06 |
| MACD | -0.30 | 2.79 |
| Stochastic Oscillator | 5.75 | 91.97 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.